Literature DB >> 18505804

Oral vaccination against bubonic plague using a live avirulent Yersinia pseudotuberculosis strain.

Thierry Blisnick1, Patrick Ave, Michel Huerre, Elisabeth Carniel, Christian E Demeure.   

Abstract

We evaluated the possibility of using Yersinia pseudotuberculosis as a live vaccine against plague because it shares high genetic identity with Y. pestis while being much less virulent, genetically much more stable, and deliverable orally. A total of 41 Y. pseudotuberculosis strains were screened by PCR for the absence of the high pathogenicity island, the superantigens YPM, and the type IV pilus and the presence of the pYV virulence plasmid. One strain (IP32680) fulfilled these criteria. This strain was avirulent in mice upon intragastric or subcutaneous inoculation and persisted for 2 months in the mouse intestine without clinical signs of disease. IP32680 reached the mesenteric lymph nodes, spleen, and liver without causing major histological lesions and was cleared after 13 days. The antibodies produced in vaccinated animals recognized both Y. pseudotuberculosis and Y. pestis antigens efficiently. After a subcutaneous challenge with Y. pestis CO92, bacteria were found in low amounts in the organs and rarely in the blood of vaccinated animals. One oral IP32680 inoculation protected 75% of the mice, and two inoculations induced much higher antibody titers and protected 88% of the mice. Our results thus validate the concept that an attenuated Y. pseudotuberculosis strain can be an efficient, inexpensive, safe, and easy-to-produce live vaccine for oral immunization against bubonic plague.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18505804      PMCID: PMC2493205          DOI: 10.1128/IAI.00034-08

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  50 in total

1.  An unusual strain of Pasteurella pestis isolated from a fatal human case of plague.

Authors:  C C WINTER; W B CHERRY; M D MOODY
Journal:  Bull World Health Organ       Date:  1960       Impact factor: 9.408

Review 2.  Mucosal immunity and vaccines.

Authors:  Jan Holmgren; Cecil Czerkinsky
Journal:  Nat Med       Date:  2005-04       Impact factor: 53.440

Review 3.  Role of macrophage apoptosis in the pathogenesis of Yersinia.

Authors:  Y Zhang; J B Bliska
Journal:  Curr Top Microbiol Immunol       Date:  2005       Impact factor: 4.291

4.  Fraction 1 capsular antigen (F1) purification from Yersinia pestis CO92 and from an Escherichia coli recombinant strain and efficacy against lethal plague challenge.

Authors:  G P Andrews; D G Heath; G W Anderson; S L Welkos; A M Friedlander
Journal:  Infect Immun       Date:  1996-06       Impact factor: 3.441

5.  Multidrug resistance in Yersinia pestis mediated by a transferable plasmid.

Authors:  M Galimand; A Guiyoule; G Gerbaud; B Rasoamanana; S Chanteau; E Carniel; P Courvalin
Journal:  N Engl J Med       Date:  1997-09-04       Impact factor: 91.245

6.  The SCID/Beige mouse as a model to investigate protection against Yersinia pestis.

Authors:  M Green; D Rogers; P Russell; A J Stagg; D L Bell; S M Eley; R W Titball; E D Williamson
Journal:  FEMS Immunol Med Microbiol       Date:  1999-02

7.  Passive immunity to infection with Yersinia spp. mediated by anti-recombinant V antigen is dependent on polymorphism of V antigen.

Authors:  A Roggenkamp; A M Geiger; L Leitritz; A Kessler; J Heesemann
Journal:  Infect Immun       Date:  1997-02       Impact factor: 3.441

8.  Protection against experimental bubonic and pneumonic plague by a recombinant capsular F1-V antigen fusion protein vaccine.

Authors:  D G Heath; G W Anderson; J M Mauro; S L Welkos; G P Andrews; J Adamovicz; A M Friedlander
Journal:  Vaccine       Date:  1998-07       Impact factor: 3.641

9.  Short- and long-term efficacy of single-dose subunit vaccines against Yersinia pestis in mice.

Authors:  G W Anderson; D G Heath; C R Bolt; S L Welkos; A M Friedlander
Journal:  Am J Trop Med Hyg       Date:  1998-06       Impact factor: 2.345

10.  Active immunization with recombinant V antigen from Yersinia pestis protects mice against plague.

Authors:  S E Leary; E D Williamson; K F Griffin; P Russell; S M Eley; R W Titball
Journal:  Infect Immun       Date:  1995-08       Impact factor: 3.441

View more
  19 in total

Review 1.  Principles of antidote pharmacology: an update on prophylaxis, post-exposure treatment recommendations and research initiatives for biological agents.

Authors:  S Ramasamy; C Q Liu; H Tran; A Gubala; P Gauci; J McAllister; T Vo
Journal:  Br J Pharmacol       Date:  2010-10       Impact factor: 8.739

2.  A protective epitope in type III effector YopE is a major CD8 T cell antigen during primary infection with Yersinia pseudotuberculosis.

Authors:  Yue Zhang; Patricio Mena; Galina Romanov; Jr-Shiuan Lin; Stephen T Smiley; James B Bliska
Journal:  Infect Immun       Date:  2011-11-07       Impact factor: 3.441

3.  Humoral immune responses and protective efficacy of sequential B- and T-cell epitopes of V antigen of Yersinia pestis by intranasal immunization in microparticles.

Authors:  Jayaprakash Babu Uppada; Arif Azam Khan; Ajaz Ahmad Bhat; Ranjana Deshmukh; Donthamsetty Nageswara Rao
Journal:  Med Microbiol Immunol       Date:  2009-09-25       Impact factor: 3.402

Review 4.  Developing live vaccines against plague.

Authors:  Wei Sun; Kenneth L Roland; Roy Curtiss
Journal:  J Infect Dev Ctries       Date:  2011-09-14       Impact factor: 0.968

5.  Oral administration of a recombinant attenuated Yersinia pseudotuberculosis strain elicits protective immunity against plague.

Authors:  Wei Sun; Shilpa Sanapala; Hannah Rahav; Roy Curtiss
Journal:  Vaccine       Date:  2015-10-26       Impact factor: 3.641

6.  LcrV delivered via type III secretion system of live attenuated Yersinia pseudotuberculosis enhances immunogenicity against pneumonic plague.

Authors:  Wei Sun; Shilpa Sanapala; Jeremy C Henderson; Shandiin Sam; Joseph Olinzock; M Stephen Trent; Roy Curtiss
Journal:  Infect Immun       Date:  2014-08-11       Impact factor: 3.441

7.  Protection against pneumonic plague following oral immunization with a non-replicating vaccine.

Authors:  Abby Jones; Catharine Bosio; Angela Duffy; Andrew Goodyear; Martin Schriefer; Steven Dow
Journal:  Vaccine       Date:  2010-06-19       Impact factor: 3.641

Review 8.  Plague Vaccines: Status and Future.

Authors:  Wei Sun
Journal:  Adv Exp Med Biol       Date:  2016       Impact factor: 2.622

9.  The smpB-ssrA mutant of Yersinia pestis functions as a live attenuated vaccine to protect mice against pulmonary plague infection.

Authors:  Nihal A Okan; Patricio Mena; Jorge L Benach; James B Bliska; A Wali Karzai
Journal:  Infect Immun       Date:  2010-01-11       Impact factor: 3.441

Review 10.  Human gut-associated lymphoid tissues (GALT); diversity, structure, and function.

Authors:  Urs M Mörbe; Peter B Jørgensen; Thomas M Fenton; Nicole von Burg; Lene B Riis; Jo Spencer; William W Agace
Journal:  Mucosal Immunol       Date:  2021-03-22       Impact factor: 7.313

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.